{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T02:03:44Z","timestamp":1777341824001,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Capital Health Development Fund","award":["201614035"],"award-info":[{"award-number":["201614035"]}]},{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2016-I2M-1-011"],"award-info":[{"award-number":["2016-I2M-1-011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The risk of liver fibrosis in non-alcoholic fatty liver disease (NAFLD) can be easily evaluated by noninvasive scoring systems, of which the NAFLD fibrosis score (NFS) is the most commonly used. Proprotein convertase subtilisin\/kexin type 9 (PCSK9), a new predictor of cardiovascular events, has been reported to be associated with cardiovascular outcomes and NAFLD. However, the relationship of NFS with PCSK9 and their prognostic abilities in cardiovascular risks are unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 2008 hospitalized subjects who had chest pain without lipid-lowering therapy were consecutively included. Baseline clinical data were collected, and the NFS was calculated. The circulating PCSK9 concentration was determined by enzyme immunoassay. The major adverse cardiovascular event (MACE) occurrences were recorded in the follow-up period. Associations of PCSK9 concentration with NFS were examined. All of the participants were categorized into three groups according to NFS levels and were further stratified by PCSK9 tertiles to evaluate the MACEs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>158 (7.87%) MACEs were observed during a mean of 3.2\u2009years of follow-up. NFS levels were independently related to higher PCSK9 levels according to multivariable linear regression analysis. Furthermore, elevated PCSK9 and NFS concentrations were respectively associated with increased MACE incidence in multivariable Cox regression models. When combining NFS status with PCSK9 tertiles as a stratifying factor, patients with intermediate-high NFS and high PCSK9 levels had higher risks of events than those with low NFS and low PCSK9 levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study revealed for the first time that NFS is positively related to PCSK9 and that the combination of NFS and PCSK9 greatly increased the risk of MACEs in patients with chest pain, providing a potential link between NFS and PCSK9 for predicting cardiovascular events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12944-021-01610-w","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T19:02:48Z","timestamp":1641582168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study"],"prefix":"10.1186","volume":"21","author":[{"given":"Jia","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Lu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye-Xuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Lin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na-Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Gang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Xia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"issue":"1","key":"1610_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"1610_CR2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577\u201386. https:\/\/doi.org\/10.1002\/hep.28785.","journal-title":"Hepatology"},{"issue":"6","key":"1610_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, Hammar U, St\u00e5l P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265\u201373. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.027.","journal-title":"J Hepatol"},{"issue":"1","key":"1610_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/hep.29113","volume":"66","author":"A Unalp-Arida","year":"2017","unstructured":"Unalp-Arida A, Ruhl CE. Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology. 2017;66(1):84\u201395. https:\/\/doi.org\/10.1002\/hep.29113.","journal-title":"Hepatology"},{"issue":"2","key":"1610_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","volume":"68","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68(2):305\u201315. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.013.","journal-title":"J Hepatol"},{"key":"1610_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.atherosclerosis.2020.03.010","volume":"299","author":"Q Chen","year":"2020","unstructured":"Chen Q, Li Q, Li D, Chen X, Liu Z, Hu G, et al. Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease. Atherosclerosis. 2020;299:45\u201352. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.03.010.","journal-title":"Atherosclerosis"},{"issue":"11","key":"1610_CR7","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3748\/wjg.v25.i11.1307","volume":"25","author":"JH Zhou","year":"2019","unstructured":"Zhou JH, Cai JJ, She ZG, Li HL. Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice. World J Gastroenterol. 2019;25(11):1307\u201326. https:\/\/doi.org\/10.3748\/wjg.v25.i11.1307.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"1610_CR8","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","volume":"114","author":"NG Seidah","year":"2014","unstructured":"Seidah NG, Awan Z, Chr\u00e9tien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114(6):1022\u201336. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.301621.","journal-title":"Circ Res"},{"issue":"13","key":"1610_CR9","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1161\/CIRCULATIONAHA.115.018531","volume":"133","author":"K Leander","year":"2016","unstructured":"Leander K, M\u00e4larstig A, Van\u2019t Hooft FM, Hyde C, Hell\u00e9nius M-L, Troutt JS, et al. Circulating Proprotein convertase Subtilisin\/Kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors. Circulation. 2016;133(13):1230\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018531.","journal-title":"Circulation"},{"issue":"8","key":"1610_CR10","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.ajpath.2021.04.016","volume":"191","author":"C Macchi","year":"2021","unstructured":"Macchi C, Ferri N, Sirtori CR, Corsini A, Banach M, Ruscica M. Proprotein convertase Subtilisin\/Kexin type 9: a view beyond the canonical cholesterol-lowering impact. Am J Pathol. 2021;191(8):1385\u201397. https:\/\/doi.org\/10.1016\/j.ajpath.2021.04.016.","journal-title":"Am J Pathol"},{"key":"1610_CR11","doi-asserted-by":"crossref","unstructured":"Cesaro A, Bianconi V, Gragnano F, Moscarella E, Fimiani F, Monda E, et al. Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin\/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. BioFactors (Oxford, England). 2020.","DOI":"10.1002\/biof.1619"},{"issue":"12","key":"1610_CR12","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264\u201372. https:\/\/doi.org\/10.1056\/NEJMoa054013.","journal-title":"N Engl J Med"},{"issue":"5","key":"1610_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","volume":"48","author":"M Ruscica","year":"2016","unstructured":"Ruscica M, Ferri N, Macchi C, Meroni M, Lanti C, Ricci C, et al. Liver fat accumulation is associated with circulating PCSK9. Ann Med. 2016;48(5):384\u201391. https:\/\/doi.org\/10.1080\/07853890.2016.1188328.","journal-title":"Ann Med"},{"issue":"6","key":"1610_CR14","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005\u201323. https:\/\/doi.org\/10.1002\/hep.25762.","journal-title":"Hepatology"},{"issue":"1","key":"1610_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/hep.24376","volume":"54","author":"AJ Sanyal","year":"2011","unstructured":"Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54(1):344\u201353. https:\/\/doi.org\/10.1002\/hep.24376.","journal-title":"Hepatology"},{"key":"1610_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2018.07.030","volume":"277","author":"Y-X Cao","year":"2018","unstructured":"Cao Y-X, Liu H-H, Sun D, Jin J-L, Xu R-X, Guo Y-L, et al. The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia. Atherosclerosis. 2018;277:7\u201314. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.07.030.","journal-title":"Atherosclerosis"},{"issue":"4","key":"1610_CR17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846\u201354. https:\/\/doi.org\/10.1002\/hep.21496.","journal-title":"Hepatology"},{"issue":"6","key":"1610_CR18","doi-asserted-by":"publisher","first-page":"e195844","DOI":"10.1001\/jamanetworkopen.2019.5844","volume":"2","author":"DB Rosoff","year":"2019","unstructured":"Rosoff DB, Charlet K, Jung J, Lee J, Muench C, Luo A, et al. Association of High-Intensity Binge Drinking with Lipid and Liver Function Enzyme Levels. JAMA Netw Open. 2019;2(6):e195844. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.5844.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"1610_CR19","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/mp.2017.168","volume":"23","author":"FW Lohoff","year":"2018","unstructured":"Lohoff FW, Sorcher JL, Rosen AD, Mauro KL, Fanelli RR, Momenan R, et al. Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder. Mol Psychiatry. 2018;23(9):1900\u201310. https:\/\/doi.org\/10.1038\/mp.2017.168.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"1610_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1177\/2047487319880985","volume":"204748731988098","author":"YX Cao","year":"2019","unstructured":"Cao YX, Liu HH, Jin JL, Sun D, Guo YL, Wu NQ, et al. Plasma proprotein convertase subtilisin\/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia. Eur J Prev Cardiol. 2019;2047487319880985(3):272\u20139. https:\/\/doi.org\/10.1177\/2047487319880985.","journal-title":"Eur J Prev Cardiol"},{"issue":"52","key":"1610_CR21","doi-asserted-by":"publisher","first-page":"e2426","DOI":"10.1097\/MD.0000000000002426","volume":"94","author":"J-J Li","year":"2015","unstructured":"Li J-J, Li S, Zhang Y, Xu R-X, Guo Y-L, Zhu C-G, et al. Proprotein convertase Subtilisin\/Kexin type 9, C-reactive protein, coronary severity, and outcomes in patients with stable coronary artery disease: a prospective observational cohort study. Medicine. 2015;94(52):e2426. https:\/\/doi.org\/10.1097\/MD.0000000000002426.","journal-title":"Medicine"},{"issue":"6","key":"1610_CR22","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/2047487318815320","volume":"26","author":"C Macchi","year":"2019","unstructured":"Macchi C, Ferri N, Favero C, Cantone L, Vigna L, Pesatori AC, et al. Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin\/kexin type 9 in obese individuals. Eur J Prev Cardiol. 2019;26(6):578\u201388. https:\/\/doi.org\/10.1177\/2047487318815320.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"1610_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.vph.2014.03.004","volume":"62","author":"C Werner","year":"2014","unstructured":"Werner C, Hoffmann MM, Winkler K, B\u00f6hm M, Laufs U. Risk prediction with proprotein convertase subtilisin\/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vasc Pharmacol. 2014;62(2):94\u2013102. https:\/\/doi.org\/10.1016\/j.vph.2014.03.004.","journal-title":"Vasc Pharmacol"},{"key":"1610_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.atherosclerosis.2016.07.922","volume":"252","author":"C Vlachopoulos","year":"2016","unstructured":"Vlachopoulos C, Terentes-Printzios D, Georgiopoulos G, Skoumas I, Koutagiar I, Ioakeimidis N, et al. Prediction of cardiovascular events with levels of proprotein convertase subtilisin\/kexin type 9: a systematic review and meta-analysis. Atherosclerosis. 2016;252:50\u201360. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.07.922.","journal-title":"Atherosclerosis"},{"issue":"10","key":"1610_CR25","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1161\/ATVBAHA.115.306172","volume":"35","author":"YM Zhu","year":"2015","unstructured":"Zhu YM, Anderson TJ, Sikdar K, Fung M, McQueen MJ, Lonn EM, et al. Association of Proprotein Convertase Subtilisin\/Kexin type 9 (PCSK9) with cardiovascular risk in primary prevention. Arterioscler Thromb Vasc Biol. 2015;35(10):2254\u20139. https:\/\/doi.org\/10.1161\/ATVBAHA.115.306172.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"1610_CR26","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1093\/eurheartj\/ehv568","volume":"37","author":"PM Ridker","year":"2016","unstructured":"Ridker PM, Rifai N, Bradwin G, Rose L. Plasma proprotein convertase subtilisin\/kexin type 9 levels and the risk of first cardiovascular events. Eur Heart J. 2016;37(6):554\u201360. https:\/\/doi.org\/10.1093\/eurheartj\/ehv568.","journal-title":"Eur Heart J"},{"key":"1610_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2018.01.025","volume":"130","author":"A Baragetti","year":"2018","unstructured":"Baragetti A, Grejtakova D, Casula M, Olmastroni E, Jotti GS, Norata GD, et al. Proprotein convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: facts and gaps. Pharmacol Res. 2018;130:1\u201311. https:\/\/doi.org\/10.1016\/j.phrs.2018.01.025.","journal-title":"Pharmacol Res"},{"issue":"14","key":"1610_CR28","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.jacc.2021.07.056","volume":"78","author":"C Oleaga","year":"2021","unstructured":"Oleaga C, Shapiro MD, Hay J, Mueller PA, Miles J, Huang C, et al. Hepatic sensing loop regulates PCSK9 secretion in response to inhibitory antibodies. J Am Coll Cardiol. 2021;78(14):1437\u201349. https:\/\/doi.org\/10.1016\/j.jacc.2021.07.056.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1610_CR29","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3748\/wjg.v19.i8.1219","volume":"19","author":"S Treeprasertsuk","year":"2013","unstructured":"Treeprasertsuk S, Bj\u00f6rnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol. 2013;19(8):1219\u201329. https:\/\/doi.org\/10.3748\/wjg.v19.i8.1219.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1610_CR30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1053\/j.gastro.2019.09.008","volume":"158","author":"H Hagstr\u00f6m","year":"2020","unstructured":"Hagstr\u00f6m H, Talb\u00e4ck M, Andreasson A, Walldius G, Hammar N. Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease. Gastroenterology. 2020;158(1):200\u201314. https:\/\/doi.org\/10.1053\/j.gastro.2019.09.008.","journal-title":"Gastroenterology"},{"key":"1610_CR31","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","volume":"145","author":"P Angulo","year":"2013","unstructured":"Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:782\u2013789.e784.","journal-title":"Gastroenterology"},{"issue":"1","key":"1610_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/0003319719844933","volume":"71","author":"Y Turan","year":"2020","unstructured":"Turan Y. The nonalcoholic fatty liver disease fibrosis score is related to Epicardial fat thickness and complexity of coronary artery disease. Angiology. 2020;71(1):77\u201382. https:\/\/doi.org\/10.1177\/0003319719844933.","journal-title":"Angiology"},{"issue":"6","key":"1610_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jhepr.2019.10.009","volume":"1","author":"PF Lebeau","year":"2019","unstructured":"Lebeau PF, Byun JH, Platko K, Al-Hashimi AA, Lhot\u00e1k \u0160, MacDonald ME, et al. Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. JHEP Rep. 2019;1(6):418\u201329. https:\/\/doi.org\/10.1016\/j.jhepr.2019.10.009.","journal-title":"JHEP Rep"},{"issue":"23","key":"1610_CR34","doi-asserted-by":"publisher","first-page":"9037","DOI":"10.1074\/jbc.RA119.008094","volume":"294","author":"PF Lebeau","year":"2019","unstructured":"Lebeau PF, Byun JH, Platko K, MacDonald ME, Poon SV, Faiyaz M, et al. Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice. J Biol Chem. 2019;294(23):9037\u201347. https:\/\/doi.org\/10.1074\/jbc.RA119.008094.","journal-title":"J Biol Chem"},{"issue":"3","key":"1610_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589\u2013600. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.013.","journal-title":"J Hepatol"},{"issue":"8","key":"1610_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.cgh.2012.03.011","volume":"10","author":"DM Torres","year":"2012","unstructured":"Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10(8):837\u201358. https:\/\/doi.org\/10.1016\/j.cgh.2012.03.011.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1610_CR37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149:389\u2013397.e310.","journal-title":"Gastroenterology"},{"issue":"1","key":"1610_CR38","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12933-019-0949-3","volume":"18","author":"C Caselli","year":"2019","unstructured":"Caselli C, Del Turco S, Ragusa R, Lorenzoni V, De Graaf M, Basta G, et al. Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. Cardiovasc Diabetol. 2019;18(1):144. https:\/\/doi.org\/10.1186\/s12933-019-0949-3.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1610_CR39","doi-asserted-by":"publisher","first-page":"17167","DOI":"10.1038\/s41598-019-53603-6","volume":"9","author":"JS Lee","year":"2019","unstructured":"Lee JS, Mukhopadhyay P, Matyas C, Trojnar E, Paloczi J, Yang YR, et al. PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease. Sci Rep. 2019;9(1):17167. https:\/\/doi.org\/10.1038\/s41598-019-53603-6.","journal-title":"Sci Rep"},{"issue":"1","key":"1610_CR40","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1038\/s41598-018-35773-x","volume":"9","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Wei TF, Zhao B, Yin Z, Shi QX, Liu PL, et al. Sex differences associated with circulating PCSK9 in patients presenting with acute myocardial infarction. Sci Rep. 2019;9(1):3113. https:\/\/doi.org\/10.1038\/s41598-018-35773-x.","journal-title":"Sci Rep"},{"key":"1610_CR41","doi-asserted-by":"publisher","first-page":"738218","DOI":"10.3389\/fphys.2021.738218","volume":"12","author":"K Ueda","year":"2021","unstructured":"Ueda K, Fukuma N, Adachi Y, Numata G, Tokiwa H, Toyoda M, et al. Sex differences and regulatory actions of estrogen in cardiovascular system. Front Physiol. 2021;12:738218. https:\/\/doi.org\/10.3389\/fphys.2021.738218.","journal-title":"Front Physiol"},{"issue":"1","key":"1610_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12944-021-01431-x","volume":"20","author":"S Feder","year":"2021","unstructured":"Feder S, Wiest R, Weiss TS, Aslanidis C, Schacherer D, Krautbauer S, et al. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis. Lipids Health Dis. 2021;20(1):6. https:\/\/doi.org\/10.1186\/s12944-021-01431-x.","journal-title":"Lipids Health Dis"},{"issue":"2","key":"1610_CR43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/liv.14711","volume":"41","author":"S Grimaudo","year":"2021","unstructured":"Grimaudo S, Bartesaghi S, Rametta R, Marra F, Margherita Mancina R, Pihlajam\u00e4ki J, et al. PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. Liver Int. 2021;41(2):321\u201332. https:\/\/doi.org\/10.1111\/liv.14711.","journal-title":"Liver Int"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01610-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-021-01610-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01610-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T19:11:05Z","timestamp":1641582665000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-021-01610-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1610"],"URL":"https:\/\/doi.org\/10.1186\/s12944-021-01610-w","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]},"assertion":[{"value":"4 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the Declaration of Helsinki and was approved by the local ethics committees (Fu Wai Hospital & National Center for Cardiovascular Diseases, Beijing, China, approval number: 2013\u2013442) were obtained. The informed written consents were obtained from enrolled patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared that they have no conflict of interest with respect to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}